Picture Berlin Partner Health Capital Computational Biology 2022 650x100px
Organisation › Details

Hemispherian AS

Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company’s lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway. *


Period Start 2021-05-10 existent
Products Industry small-molecule cancer drug
  Industry 2 drug development
Person Person Albisser, Zeno (Hemispherian 202105 CEO)
Region Region Oslo
  Country Norway
  Street 21 Gaustadalléen
  City 0349 Oslo
  Tel +47-406-03455
    Address record changed: 2021-05-10
Basic data Employees n. a.
    * Document for �About Section�: Hemispherian AS. (5/3/22). "Press Release: Hemispherian Raises Seed Funding for Novel Cancer Therapeutics". Oslo.
Record changed: 2022-05-03


Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

More documents for Hemispherian AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BioPharm Amercia 2022 Boston 650x300px

» top